The European Union has approved deals involving drugmakers Novartis and GlaxoSmithKline, provided they sell off assets in the vaccines and consumer health businesses.
The European Commission had feared that the transactions, as initially planned, would undermine competition in vaccines against meningitis and diphtheria as well as in a range of consumer health products to stop smoking and to treat cold sores, cold and influenza.
To tackle the commission’s concerns, GSK pledged to “grant a worldwide, exclusive, perpetual license of GSK’s Nimenrix vaccine for bacterial meningitis and divest GSK’s Mencevax vaccine for bacterial meningitis worldwide,” the commission said.
GSK also pledged to conclude supply, distribution and transfer agreements for Novartis’s vaccines against diphtheria and tetanus.
GSK’s purchase of Novartis’s vaccines was for up to $7.1 billion.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI